Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00371709 · ClinicalTrials.gov registry record · Phase 3
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 871
- Enrollment target
NCT00371709 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 871 participants.
The verdict
NCT00371709, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 871 participants
- Enrollment target
Study Summary
TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control. The control group is a case-matched, blended population of TAXUS Express patients from the TAXUS IV and TAXUS V de novo clinical trials. The objective of the study is to evaluate clinical outcomes of TAXUS Liberté-SR stent in de novo lesions and to assess the non-inferiority of TAXUS Liberté versus TAXUS Express. The TAXUS Liberté-SR stent is hypothesized to have comparable safety and efficacy to the TAXUS Express stent.
Interventions
- DEVICE TAXUS Liberté-SR
- DEVICE TAXUS™ Express
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 871 participants |
| Start Date | 2004-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00371709
The ClinicalTrials.gov registry entry for NCT00371709 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 871 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAXUS Liberté-SR is the first listed.
NCT00371709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00371709 about?
NCT00371709 is a clinical study titled "TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions". TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control. The control group is a case-matched, blended population of TAXUS Express patients from the TAXUS IV and TAXUS V de nov...
What is the current status of trial NCT00371709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 871 participants. The study started on 2004-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00371709?
The interventions under investigation include: TAXUS Liberté-SR (DEVICE), TAXUS™ Express (DEVICE).
Who is sponsoring clinical trial NCT00371709?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.